The latest from CDMOs, CMOs, and suppliers featuring NewBiologix and Scinai Bioservices.  

Biologics Manufacturing 
* Cell & Gene Therapy Service Provider, NewBiologix, Launches US Subsidiary 
General 
* Scinai Bioservices Launches US Subsidiary 

---

Biologics Manufacturing 

Cell & Gene Therapy Service Provider, NewBiologix, Launches US Subsidiary 
NewBiologix, a Lausanne, Switzerland-based provider of cell- & gene-therapy services, has announced the launch of a new US subsidiary. In making the move, the company appointed David Kelly as Business Development Manager to lead the US operation and head business development. He has more than a decade of experience in gene and cell therapy as well as stem-cell manufacturing and commercial development. He will oversee sales and support for NewBiologix services and licensing opportunities for clients across the US and Canada. 

Source: NewBiologix 

---

General 

Scinai Bioservices Launches US Subsidiary 
Scinai Immunotherapeutics, a Jerusalem, Israel-based bio/pharmaceutical company specializing in developing immunotherapies and a provider of CDMO services, has announced the establishment of a US-based subsidiary for its CDMO services, Scinai Bioservices.  

In 2024, Scinai launched its CDMO business unit, Scinai Bioservices, operating from the company’s site in Jerusalem to provide upstream and downstream process development, scale-up, analytical methods development, and drug manufacturing for preclinical and clinical supplies. Its facility includes 1,850 square meters for GMP cleanrooms and laboratories and provides biologic drug-substance development and manufacturing (fermentation up to 300 L) and supporting suites for aseptic fill-finish. Scinai’s new US subsidiary, Scinai Bioservices Inc., aims to serve US-based early-stage biotech companies. 

Source: Scinai Immunotherapies